Camille Taille
Elite in Eosinophilic Asthma

Camille Taille

CHU Avicenne, AP HP
Bobigny, FR 
Elite in Eosinophilic Asthma
CHU Avicenne, AP HP
Bobigny, FR 
OverviewLocationsClinical Research

Overview

Camille Taille practices in Bobigny, France. Ms. Taille is rated as an Elite expert by MediFind in the treatment of Eosinophilic Asthma. Her top areas of expertise are Asthma, Eosinophilic Asthma, Granulomatosis with Polyangiitis, Lung Transplant, and Cardiac Ablation.

Her clinical research consists of co-authoring 181 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 11 articles and participated in 1 clinical trial in the study of Eosinophilic Asthma.

Gender
Female

Locations

CHU Avicenne, AP HP
Bobigny, France
Other Locations
Paris, France
Toulouse, France
Université Paris Est Créteil, Creteil, France
France
191 Avenue Du Doyen Giraud, 34295 Montpellier Cedex 5, Montpellier, 34295, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
Enrollment Status: Completed
Publish Date: October 15, 2025
Intervention Type: Biological, Drug, Device
Study Drugs: Depemokimab, Mepolizumab, Benralizumab
Study Phase: Phase 3
A Multi-center, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Compare Cessation Versus Continuation of Long-term Mepolizumab Treatment in Patients With Severe Eosinophilic Asthma (201810)
A Multi-center, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Compare Cessation Versus Continuation of Long-term Mepolizumab Treatment in Patients With Severe Eosinophilic Asthma (201810)
Enrollment Status: Completed
Publish Date: February 05, 2020
Intervention Type: Drug, Biological
Study Phase: Phase 3
View 1 Less Clinical Trial

180 Total Publications

Rituximab Versus Conventional Therapy for Remission Induction in Eosinophilic Granulomatosis With Polyangiitis : A Randomized Controlled Trial.
Rituximab Versus Conventional Therapy for Remission Induction in Eosinophilic Granulomatosis With Polyangiitis : A Randomized Controlled Trial.
Journal: Annals of internal medicine
Published: July 28, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Taille's expertise for a condition
ConditionClose
View All 17 Advanced Conditions
View All 35 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile